Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma

Andrew Wood, Kateryna Krytska, Hannah T. Ryles, Nicole R. Infarinato, Renata Sano, Theodore D. Hansel, Lori S. Hart, Frederick J. King, Timothy R. Smith, Edward Ainscow, Kathryn B. Grandinetti, Tove Tuntland, Sunkyu Kim, Giordano Caponigro, You He, Shiva Krupa, Nanxin Li, Jennifer L. Harris, Yaël P. MosséClinical 2016 · DOI

Abstract

<b>Purpose:</b> Anaplastic lymphoma kinase (<i>ALK</i>) is the most frequently mutated oncogene in the pediatric cancer neuroblastoma. We performed an <i>in vitro</i> screen for synergistic drug combinations that target neuroblastomas with mutations in <i>ALK</i> to determine whether drug combinations could enhance antitumor efficacy.<b>Experimental Design:</b> We screened combinations of eight molecularly targeted agents against 17 comprehensively characterized human neuroblastoma-derived cell lines. We investigated the combination of ceritinib and ribociclib on <i>in vitro</i> proliferation, cell cycle, viability, caspase activation, and the cyclin D/CDK4/CDK6/RB and pALK signaling networks in cell lines with representative ALK status. We performed <i>in vivo</i> trials in CB17 SCID mice bearing conventional and patient-derived xenograft models comparing ceritinib alone, ribociclib alone, and the combination, with plasma pharmacokinetics to evaluate for drug-drug interactions.<b>Results:</b> The combination of ribociclib, a dual inhibitor of cyclin-dependent kinase (CDK) 4 and 6, and the ALK inhibitor ceritinib demonstrated higher cytotoxicity (<i>P</i> = 0.008) and synergy scores (<i>P</i> = 0.006) in cell lines with <i>ALK</i> mutations as compared with cell lines lacking mutations or alterations in <i>ALK</i> Compared with either drug alone, combination therapy enhanced growth inhibition, cell-cycle arrest, and caspase-independent cell death. Combination therapy achieved complete regressions in neuroblastoma xenografts with <i>ALK</i>-F1174L and F1245C <i>de novo</i> resistance mutations and prevented the emergence of resistance. Murine ribociclib and ceritinib plasma concentrations were unaltered by combination therapy.<b>Conclusions:</b> This preclinical combination drug screen with <i>in vivo</i> validation has provided the rationale for a first-in-children trial of combination ceritinib and ribociclib in a molecularly selected pediatric population. <i>Clin Cancer Res; 23(11); 2856-68. ©2016 AACR</i>.
BibTeX
@inproceedings{wood2016dual,
  author = {Andrew Wood and Kateryna Krytska and Hannah T. Ryles and Nicole R. Infarinato and Renata Sano and Theodore D. Hansel and Lori S. Hart and Frederick J. King and Timothy R. Smith and Edward Ainscow and Kathryn B. Grandinetti and Tove Tuntland and Sunkyu Kim and Giordano Caponigro and You He and Shiva Krupa and Nanxin Li and Jennifer L. Harris and Yaël P. Mossé},
  title = {{Dual <i>ALK</i> and <i>CDK4/6</i> Inhibition Demonstrates Synergy against Neuroblastoma}},
  booktitle = {Clinical},
  year = {2016},
  doi = {10.1158/1078-0432.ccr-16-1114},
}

Loading related content...

Figure